citalopram has been researched along with Drug Withdrawal Symptoms in 34 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a case of serotonin syndrome secondary to clozapine withdrawal and concomitant use of citalopram hydrobromide, a phenomenon that has been rarely reported." | 7.79 | Serotonin syndrome associated with clozapine withdrawal. ( Burns, JD; Green, DM; Schembri, F; Stevenson, E, 2013) |
| " Escitalopram provided no advantage over placebo in either abstinence rates from cannabis or anxiety and depression scores during the withdrawal and abstinent periods." | 5.19 | Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. ( Bar-Hamburger, R; Bloch, M; Bluvstein, I; Miller, H; Rapoport, E; Schreiber, S; Weinstein, AM, 2014) |
| "We describe a case of serotonin syndrome secondary to clozapine withdrawal and concomitant use of citalopram hydrobromide, a phenomenon that has been rarely reported." | 3.79 | Serotonin syndrome associated with clozapine withdrawal. ( Burns, JD; Green, DM; Schembri, F; Stevenson, E, 2013) |
| "In the new era of naltrexone for alcohol dependence, it is notable that only 1 study to date has examined the efficacy of antidepressant medication prescribed concurrently with naltrexone." | 2.80 | A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. ( Adamson, SJ; Berks, J; Cape, G; Deering, D; Dunn, A; Foulds, JA; Frampton, CM; Nixon, L; Sellman, JD, 2015) |
| "Anhedonia is often the cause for recurrence in heroine addiction, therefore, an appropriate treatment is an important aspect in recurrence prevention and remission stabilization." | 2.71 | [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention]. ( Grinenko, AIa; Krupitskiĭ, EM; Zvartau, EE, 2003) |
| "Discontinuation or withdrawal symptoms have been documented for all major classes of antide- pressants, especially the selective serotonin reuptake inhibitors (SSRIs)." | 1.40 | Emerging mania following escitalopram withdrawal in a patient with unipolar depression managed with its reintroduction. ( DE Berardis, D; DI Giannantonio, M; Fornaro, M; Kahn, DA; Marini, S; Martinotti, G; Serroni, N; Valchera, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (11.76) | 18.2507 |
| 2000's | 19 (55.88) | 29.6817 |
| 2010's | 11 (32.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou Kassm, S | 1 |
| Naja, W | 1 |
| Stevenson, E | 1 |
| Schembri, F | 1 |
| Green, DM | 1 |
| Burns, JD | 1 |
| Weinstein, AM | 1 |
| Miller, H | 1 |
| Bluvstein, I | 1 |
| Rapoport, E | 1 |
| Schreiber, S | 1 |
| Bar-Hamburger, R | 1 |
| Bloch, M | 1 |
| Prakash, S | 1 |
| Mandal, P | 1 |
| DE Berardis, D | 1 |
| Serroni, N | 1 |
| Marini, S | 1 |
| Fornaro, M | 1 |
| Valchera, A | 1 |
| Martinotti, G | 1 |
| DI Giannantonio, M | 1 |
| Kahn, DA | 1 |
| Papp, M | 1 |
| Gruca, P | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Litwa, E | 1 |
| Willner, P | 1 |
| Adamson, SJ | 1 |
| Sellman, JD | 1 |
| Foulds, JA | 1 |
| Frampton, CM | 1 |
| Deering, D | 1 |
| Dunn, A | 1 |
| Berks, J | 1 |
| Nixon, L | 1 |
| Cape, G | 1 |
| Saglam, E | 2 |
| Ates, LE | 1 |
| Kayir, H | 2 |
| Celik, T | 2 |
| Terzioglu, B | 1 |
| Uzbay, T | 2 |
| Chakraborty, R | 1 |
| Chatterjee, A | 1 |
| Chaudhury, S | 1 |
| Andersen, CL | 1 |
| Videbech, P | 1 |
| Bosker, FJ | 1 |
| Tanke, MA | 1 |
| Jongsma, ME | 1 |
| Cremers, TI | 1 |
| Jagtman, E | 1 |
| Pietersen, CY | 1 |
| van der Hart, MG | 1 |
| Gladkevich, AV | 1 |
| Kema, IP | 1 |
| Westerink, BH | 1 |
| Korf, J | 1 |
| den Boer, JA | 1 |
| Strong, DR | 1 |
| Brown, RA | 1 |
| Sims, M | 1 |
| Herman, DS | 1 |
| Anderson, BJ | 1 |
| Stein, MD | 1 |
| Astorne Figari, WJ | 1 |
| Herrmann, S | 1 |
| Akogyeram, C | 1 |
| Qian, Q | 1 |
| Isbister, GK | 1 |
| Downes, F | 1 |
| Whyte, IM | 1 |
| Grinenko, AIa | 1 |
| Krupitskiĭ, EM | 1 |
| Zvartau, EE | 1 |
| Adson, DE | 1 |
| Kotlyar, M | 1 |
| Wu, CC | 1 |
| Chen, JY | 1 |
| Tao, PL | 1 |
| Chen, YA | 1 |
| Yeh, GC | 1 |
| van Geffen, EC | 1 |
| Hugtenburg, JG | 1 |
| Heerdink, ER | 1 |
| van Hulten, RP | 1 |
| Egberts, AC | 1 |
| Baldwin, DS | 1 |
| Montgomery, SA | 2 |
| Nil, R | 1 |
| Lader, M | 1 |
| Feth, N | 1 |
| Cattapan-Ludewig, K | 1 |
| Jaquenoud Sirot, E | 1 |
| Kapetanovic, S | 1 |
| Simpson, GM | 1 |
| Kwon, P | 1 |
| Lefkowitz, W | 1 |
| Prakash, O | 1 |
| Dhar, V | 1 |
| Gram, LF | 1 |
| Olausson, P | 1 |
| Engel, JA | 1 |
| Söderpalm, B | 1 |
| Voirol, P | 1 |
| Rubin, C | 1 |
| Bryois, C | 1 |
| Kosel, M | 1 |
| Buclin, T | 1 |
| Baumann, P | 1 |
| Bakker, A | 1 |
| Miller, LJ | 1 |
| Sempere, E | 1 |
| Martínez, I | 1 |
| Martínez-Mir, I | 1 |
| Rey, A | 1 |
| Fernando, AT | 1 |
| Schwader, P | 1 |
| Markowitz, JS | 1 |
| DeVane, CL | 1 |
| Liston, HL | 1 |
| Eriksson, M | 1 |
| Berggren, U | 1 |
| Fahlke, C | 1 |
| Hård, E | 1 |
| Balldin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antidepressants During Office-Based Buprenorphine[NCT00475878] | Phase 3 | 147 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Depressive symptoms, as measured by self-report during study interviews, using the Beck Depression Inventory II. Scores ranged from 0-63; higher scores indicate more depressive symptoms. (NCT00475878)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| 10 mg Escitalopram | 12.31 |
| Placebo | 11.35 |
Drop-out is defined as 7 or more days of missed Buprenorphine doses (NCT00475878)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| 10 mg Escitalopram | 33.3 |
| Placebo | 44.0 |
1 review available for citalopram and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Discontinuation symptoms in depression and anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depre | 2007 |
7 trials available for citalopram and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.
Topics: Adult; Anxiety; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Dou | 2014 |
A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression.
Topics: Adult; Affect; Alcoholism; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Diagnostic | 2015 |
Persistence on a stress-challenge task before initiating buprenorphine treatment was associated with successful transition from opioid use to early abstinence.
Topics: Adult; Antidepressive Agents, Second-Generation; Buprenorphine; Citalopram; Comorbidity; Depressive | 2012 |
[Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Gen | 2003 |
Pharmacokinetic consequences of a citalopram treatment discontinuation.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Clomipramine; Female; | 1999 |
An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram.
Topics: Citalopram; Depressive Disorder; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Recu | 2000 |
Mental well-being in subjects with long-term excessive alcohol consumption: an experimental study.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Citalopram; Humans; Male; Mental Health; Middle Aged; M | 2002 |
26 other studies available for citalopram and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Looking for bipolarity in antidepressant discontinuation manic states: Update and diagnostic considerations of the phenomenon.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Child; Citalopram; Cyclothy | 2018 |
Serotonin syndrome associated with clozapine withdrawal.
Topics: Benzodiazepines; Citalopram; Clozapine; Cyproheptadine; Female; Humans; Middle Aged; Selective Serot | 2013 |
Drug trials in psychiatry: methodological issues.
Topics: Alcoholism; Chlordiazepoxide; Citalopram; Depressive Disorder; Diabetes Mellitus; Female; Humans; Hy | 2014 |
Emerging mania following escitalopram withdrawal in a patient with unipolar depression managed with its reintroduction.
Topics: Adult; Bipolar Disorder; Citalopram; Depressive Disorder; Female; Humans; Psychiatric Status Rating | 2014 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze | 2014 |
Escitalopram increases cortical nitric oxide synthase (NOS) in rat brain during ethanol withdrawal.
Topics: Animals; Brain; Cerebellum; Citalopram; Corpus Striatum; Ethanol; Frontal Lobe; Hippocampus; Hypotha | 2008 |
Withdrawal symptoms of trifluoperazine.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Depressive Disorde | 2008 |
[Discontinuation of antidepressant serotonergic antidepressant].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder; Diagnosis, | 2010 |
Biochemical and behavioral effects of long-term citalopram administration and discontinuation in rats: role of serotonin synthesis.
Topics: Animals; Behavior, Animal; Brain Chemistry; Citalopram; Depressive Disorder; Male; Rats; Rats, Wista | 2010 |
New onset hypertension following abrupt discontinuation of citalopram.
Topics: Antidepressive Agents; Blood Pressure; Citalopram; Drug Administration Schedule; Female; Humans; Hyp | 2014 |
Olanzapine and serotonin toxicity.
Topics: Antipsychotic Agents; Benzodiazepines; Citalopram; Drug Therapy, Combination; Humans; Olanzapine; Pa | 2003 |
Premature ejaculation associated with citalopram withdrawal.
Topics: Adult; Citalopram; Ejaculation; Humans; Male; Sexual Dysfunction, Physiological; Substance Withdrawa | 2003 |
Serotonin reuptake inhibitors attenuate morphine withdrawal syndrome in neonatal rats passively exposed to morphine.
Topics: Animals; Animals, Newborn; Behavior, Animal; Citalopram; Clomipramine; Female; Fluoxetine; Maternal- | 2005 |
Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
Topics: Adult; Citalopram; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Netherlands; Paroxetin | 2005 |
Electric sensations: neglected symptom of escitalopram discontinuation.
Topics: Citalopram; Confusion; Depressive Disorder; Electric Stimulation; Female; Humans; Paresthesia; Photi | 2006 |
Effects of escitalopram on ethanol withdrawal syndrome in rats.
Topics: Alcohol Drinking; Animals; Antidepressive Agents; Central Nervous System Depressants; Citalopram; Do | 2006 |
Delirium in HIV-associated dementia.
Topics: Adolescent; AIDS Dementia Complex; Antipsychotic Agents; Brain; Citalopram; Cytochrome P-450 CYP2D6 | 2006 |
By the way, doctor. My physician prescribed Celexa for me three years ago when I was upset over a family problem. I'm feeling better, and my situation has changed. I'd like to get off the medication. How do I do that?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Drug Administration Schedule; Female; Humans; | 2007 |
Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use.
Topics: Adult; Anti-Anxiety Agents; Basal Ganglia Diseases; Citalopram; Female; Humans; Infant, Newborn; Lor | 2008 |
Emergence of electric shock-like sensations on escitalopram discontinuation.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Dose-Response Relationship, Drug; Drug | 2008 |
[Withdrawal symptoms in connection with the use of selective serotonin reuptake inhibitors (SSRI)].
Topics: Adult; Antidepressive Agents; Citalopram; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine | 1998 |
Behavioral sensitization to nicotine is associated with behavioral disinhibition; counteraction by citalopram.
Topics: Animals; Citalopram; Drug Interactions; Male; Maze Learning; Motor Activity; Nicotine; Rats; Rats, S | 1999 |
[Severe withdrawal symptoms with fever upon stopping paroxetine].
Topics: Citalopram; Drug Administration Schedule; Fever; Fluvoxamine; Humans; Paroxetine; Selective Serotoni | 1999 |
Withdrawal-emergent dyskinesia in a patient taking risperidone/citalopram.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Citalopram; Dopamine Antagonis | 2000 |
[Withdrawal syndrome and cytalopram].
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Female; Humans; Substance Withdrawal Sy | 2000 |
A case of citalopram withdrawal.
Topics: Citalopram; Depressive Disorder; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; | 2000 |